Viva Biotech Holdings, a leading player in the biotechnology sector, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2008, the company has established itself as a prominent provider of drug discovery services, specialising in structure-based drug design and high-throughput screening. Viva Biotech's unique offerings include its proprietary technology platforms that enhance the efficiency of drug development processes, setting it apart in a competitive market. With a strong focus on innovation, the company has achieved significant milestones, including collaborations with major pharmaceutical firms and a robust portfolio of successful projects. Recognised for its expertise and commitment to advancing biopharmaceutical research, Viva Biotech Holdings continues to solidify its position as a trusted partner in the global biotech landscape.
How does Viva Biotech Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Viva Biotech Holdings's score of 20 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Viva Biotech Holdings reported total carbon emissions of approximately 46,731,280 kg CO2e, comprising 1,466,050 kg CO2e from Scope 1 and 45,285,230 kg CO2e from Scope 2 emissions. This marks a slight decrease from 2022, where emissions were about 46,779,490 kg CO2e. In 2021, the company recorded total emissions of approximately 37,456,150 kg CO2e, with Scope 1 emissions at 958,110 kg CO2e and Scope 2 emissions at 36,499,030 kg CO2e. The trend indicates a significant increase in emissions over the years, with 2020 emissions at approximately 28,359,960 kg CO2e and 2019 emissions at about 2,105,170 kg CO2e. Viva Biotech has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of defined reduction strategies suggests a need for further action in addressing their carbon footprint. The company operates within the biotechnology sector, which is increasingly under pressure to enhance sustainability practices and reduce greenhouse gas emissions.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Scope 1 | 152,010 | 000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 27,929,350 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viva Biotech Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.